These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 30172752)

  • 21. Prostate-specific antigen doubling time is a significant predictor of overall and disease-free survival in patients with prostate adenocarcinoma treated with brachytherapy.
    Resende Salgado L; Rhome R; Oh W; Stone N; Stock R
    Brachytherapy; 2018; 17(6):874-881. PubMed ID: 30061057
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostate-specific antigen bounce after prostate seed implantation for localized prostate cancer: descriptions and implications.
    Stock RG; Stone NN; Cesaretti JA
    Int J Radiat Oncol Biol Phys; 2003 Jun; 56(2):448-53. PubMed ID: 12738319
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostate-specific antigen bounce after curative brachytherapy for early-stage prostate cancer: A study of 274 African-Caribbean patients.
    Leduc N; Atallah V; Creoff M; Rabia N; Taouil T; Escarmant P; Vinh-Hung V
    Brachytherapy; 2015; 14(6):826-33. PubMed ID: 26489920
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of monotherapy prostate brachytherapy in patients with prostate cancer. Initial PSA and Gleason are important for recurrence?
    Galego P; Silva FC; Pinheiro LC
    Int Braz J Urol; 2015; 41(2):353-9. PubMed ID: 26005979
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure.
    Ko EC; Stone NN; Stock RG
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):600-7. PubMed ID: 21985944
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostate-specific antigen bounce after intensity-modulated radiotherapy for prostate cancer.
    Sheinbein C; Teh BS; Mai WY; Grant W; Paulino A; Butler EB
    Urology; 2010 Sep; 76(3):728-33. PubMed ID: 19616279
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship between sexual function and prostate-specific antigen bounce after iodine-125 permanent implant brachytherapy for localized prostate cancer.
    Nishihara K; Nakiri M; Chikui K; Suekane S; Matsuoka K; Hattori C; Ogo E; Abe T; Matsumoto Y; Ishitake T
    Int J Urol; 2014 Jul; 21(7):658-63. PubMed ID: 24650159
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate-specific antigen 'bounce' after permanent 125I-implant brachytherapy in Japanese men: a multi-institutional pooled analysis.
    Satoh T; Ishiyama H; Matsumoto K; Tsumura H; Kitano M; Hayakawa K; Ebara S; Nasu Y; Kumon H; Kanazawa S; Miki K; Egawa S; Aoki M; Toya K; Yorozu A; Nagata H; Saito S; Baba S
    BJU Int; 2009 Apr; 103(8):1064-8. PubMed ID: 19040526
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma.
    Stock RG; Stone NN; DeWyngaert JK; Lavagnini P; Unger PD
    Cancer; 1996 Jun; 77(11):2386-92. PubMed ID: 8635111
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy.
    Potters L; Cha C; Oshinsky G; Venkatraman E; Zelefsky M; Leibel S
    Cancer J Sci Am; 1999; 5(5):301-6. PubMed ID: 10526671
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transperineal permanent seed implantation of "low-risk" prostate cancer: 5-year-experiences in 118 patients.
    Block T; Czempiel H; Zimmermann F
    Strahlenther Onkol; 2006 Nov; 182(11):666-71. PubMed ID: 17072525
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PSA bounce after permanent implant prostate brachytherapy may mimic a biochemical failure: a study of 295 patients with a minimum 3-year followup.
    Toledano A; Chauveinc L; Flam T; Thiounn N; Solignac S; Timbert M; Rosenwald JC; Cosset JM
    Brachytherapy; 2006; 5(2):122-6. PubMed ID: 16644467
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increasing Fractional Doses Increases the Probability of Benign PSA Bounce in Patients Undergoing Definitive HDR Brachytherapy for Prostate Cancer.
    Hauck CR; Ye H; Chen PY; Gustafson GS; Limbacher A; Krauss DJ
    Int J Radiat Oncol Biol Phys; 2017 May; 98(1):108-114. PubMed ID: 28586946
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [PSA bounce after brachytherapy with permanent seed implantation for prostate cancer].
    Yagi Y; Namitome R; Kono Y; Nishiyama T; Toya K; Yorozu A; Saito S
    Nihon Hinyokika Gakkai Zasshi; 2011 Sep; 102(5):669-74. PubMed ID: 22191274
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Erectile function status is highly associated with prostate-specific antigen bounce in localized prostate cancer patients treated with permanent prostate brachytherapy.
    Matsushima M; Kikuchi E; Matsumoto K; Kosaka T; Mizuno R; Ohashi T; Mikami S; Miyajima A; Shigematsu N; Oya M
    Int J Urol; 2016 Mar; 23(3):247-52. PubMed ID: 26663514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of lower urinary symptom flare with overactive bladder symptom score and International Prostate Symptom Score in patients treated with iodine-125 implant brachytherapy: long-term follow-up experience at a single institute.
    Miyake M; Tanaka N; Asakawa I; Hori S; Morizawa Y; Tatsumi Y; Nakai Y; Inoue T; Anai S; Torimoto K; Aoki K; Hasegawa M; Fujii T; Konishi N; Fujimoto K
    BMC Urol; 2017 Aug; 17(1):62. PubMed ID: 28806948
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiparametric MRI and post implant CT-based dosimetry after prostate brachytherapy with iodine seeds: The higher the dose to the dominant index lesion, the lower the PSA bounce.
    Quivrin M; Loffroy R; Cormier L; Mazoyer F; Bertaut A; Chambade D; Martin E; Maingon P; Walker P; Créhange G
    Radiother Oncol; 2015 Nov; 117(2):258-61. PubMed ID: 26324019
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer.
    Zelefsky MJ; Wallner KE; Ling CC; Raben A; Hollister T; Wolfe T; Grann A; Gaudin P; Fuks Z; Leibel SA
    J Clin Oncol; 1999 Feb; 17(2):517-22. PubMed ID: 10080594
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relative influence of Gleason score and pretreatment PSA in predicting survival following brachytherapy for prostate cancer.
    Beyer DC; Thomas T; Hilbe J; Swenson V
    Brachytherapy; 2003; 2(2):77-84. PubMed ID: 15062144
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An eight-year experience of HDR brachytherapy boost for localized prostate cancer: biopsy and PSA outcome.
    Bachand F; Martin AG; Beaulieu L; Harel F; Vigneault E
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):679-84. PubMed ID: 18963537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.